ReviewInternal medicine (Tokyo, Japan)2023
Recent Advances in Drug Therapy for Parkinson's Disease.
Review in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta-Analysis.Movement disorders clinical practice · 2026Pooled it
- The effects of transcranial magnetic stimulation in motor symptoms of Parkinson's disease: an overview of systematic reviews with meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Efficacy and safety of acupuncture therapy for neuropsychiatric symptoms among patients with Parkinson's disease: A systematic review and meta-analysis.Clinical rehabilitation · 2024Pooled it
- Differentiation potential of human amniotic fluid derived-mesenchymal stem cells into dopaminergic neurons.Anatomy & cell biology · 2026Article
- Synthesis and characterization of chitosan-grafted-dopamine based micelles as multifunctional nanomedicines for Parkinson's disease treatment by intranasal administration.Drug delivery and translational research · 2026Article
- Parkinson's Disease and Respiratory Failure: Epidemiologic Insights of Two Decades From the CDC-WONDER Database.Brain and behavior · 2026Article
- Add-on safinamide and amantadine in Filipino Parkinson's disease patients with motor fluctuations: a retrospective exploratory cohort study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Can regulators have a role in facilitating the development of new medicines for Parkinson's disease?Journal of Parkinson's disease · 2026Review
- Mechanism-selective inhibition of α-synuclein aggregation by the chaperone-like BRICHOS domain.The Journal of biological chemistry · 2026Article
- Repurposing of doxycycline as a novel therapeutic avenue for management of parkinson's disease.Inflammopharmacology · 2026Review
- Using explainable AI to identify disease-relevant and deep brain stimulation treatment-sensitive gait features in Parkinson's disease.Journal of neuroengineering and rehabilitation · 2026Article
- Parkinson's disease: pathogenesis and therapeutic strategies.Molecular biomedicine · 2026Review
- Isotopically enrichedScientific reports · 2026Article
- Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson's disease.Drug delivery and translational research · 2026Article
- The Progress of Active Immunotherapy for Parkinson's Disease.International journal of molecular sciences · 2026Review
- Cognitive and Motor Improvements Correlated with Sleep and Activity Following Community-Based Non-contact Boxing in Patients with Parkinson Disease.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- Potential Synergistic Roles of Ketogenic Diet and Stem Cell Therapy in Parkinson's Disease: A Narrative Review.Cureus · 2026Review
- Local field potential biomarkers for adaptive deep brain stimulation in Parkinson's disease: A scoping review.Surgical neurology international · 2026Review
- Neuroprotective Effects of Huperzine B andAdvances in pharmacological and pharmaceutical sciences · 2026Article
- Research progress on the α-synuclein-lysosome axis in Parkinson's disease: molecular mechanisms of protein aggregation, autophagy dysfunction, and therapeutic targeting.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative disease manifesting with motor and non-motor symptoms. Current treatment mainly relies on medication as a symptomatic therapy modulating neurotransmitters. Dopamine replacement therapy has been established, and levodopa is the gold standard for treatment of PD. However, the emergence of motor complications, such as a wearing-off phenomenon, is a clinical problem. Both primary symptoms and motor complications have been targets for the development of treatments for PD. Recent progression in the management of motor complications is supported by newly developed agents and advances in device and formulation technology to deliver drugs continuously. Elucidation of the pathophysiology of PD and the development of disease-modifying therapy that affects the underlying fundamental pathophysiology of the disease are also progressing. In this review, we introduce current knowledge on developments concerning medications for patients with PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.